Trial Design

INSIGHTS ON CLINICAL TRIAL DESIGN

How Some Patient Organizations Are Driving Drug Development
Discover how patient-led registries are becoming a practical source of real-world evidence, drug repurposing insight, and smarter trial design.
Why Inclusive Clinical Trials Win On Science, Speed, And Spend
Sponsors who proactively integrate diversity into their trial designs from the earliest phases are finding that it’s not only a matter of fairness but a strategic advantage.
Why Data Integrity Still Matters — Even As Clinical Trials Evolve
Data integrity remains essential for compliance and patient safety. Learn strategies to maintain accuracy and reliability as clinical research evolves toward more connected, technology-driven models.
Lack Of IRT/RTSM System Reusability Surprises Every Clinical Trial Sponsor
Stop re-learning your IRT system with every new trial. Uncover why "standard" features often hide custom complexities that slow down UAT and clinical operations.

Balancing Patient Centricity With Complexity In Cancer Trials
10/28/2025

By bringing clinical research closer to where patients live and receive care, sponsors and CROs can expand reach, reduce travel burdens, and engage populations historically underrepresented in cancer studies.
Enhance Recruitment & Retention For Rare Kidney Disease Trials
8/10/2026

Though the burdens of developing treatments for rare kidney diseases are high, data-driven recruitment strategies and experienced CRO teams will help ensure accessible trials with strong enrollment.
Multi-Regional Clinical Trials: The Latest Guidance From FDA
3/12/2025

Conducting multi-regional clinical trials (MRCTs) is essential for accelerating oncology drug development and ensuring broader patient access. However, differences across regions can impact findings.
How Community Engagement Drives Better Study Outcomes
4/22/2026

Examples of how embedded community sites and local events show how authentic on‑the‑ground involvement translates into deeper patient relationships and measurable study outcomes.
The Implications Of Semaglutide's Connect To Increased Risk Of NAION
2/18/2025

Explore the implications of a connection between semaglutide and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Special And Patient Populations

Altasciences has the advanced level of clinical expertise required to successfully recruit and conduct clinical trials involving special and patient populations.
Your Top Partner For Ophthalmic Drug Development

As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.
Judi Core: Pre-Configured Solutions

Eliminate manual friction and improve trial visibility with pre-configured, validated workflows. Standardize execution and ensure audit-ready data protection across every global site.
Therapeutic Experience: Supporting Recruitment And Retention

CSS offers customized patient recruitment and retention solutions across the globe, ensuring successful enrollment for clinical trials across various therapeutic areas.
Good Clinical Practice Training That Goes Beyond The Basics

Strengthen trial compliance and data integrity by mastering GCP through practical, real-world scenarios designed to prevent costly errors and ensure audit readiness across your research team.